Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene Therapeutics's EPS (Basic) for the
three
months ended in Apr. 2026 was $-0.43.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $-2.17.
During the past 3 years, the average EPS without NRIGrowth Rate was -33.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -27.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 6 years, enGene Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -17.00% per year. The lowest was -73.50% per year. And the median was -33.80% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
enGene Therapeutics EPS (Diluted) Related Terms
enGene Therapeutics EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENGN vs VTVT, GUTS, VXRT: EPS (Diluted) Comparison
For the Biotechnology subindustry, enGene Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
enGene Therapeutics's Diluted EPS for the fiscal year that ended in Oct. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (ENGN) has a EPS (Diluted) of $-2.17 as of Apr. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on enGene Therapeutics and its competitors.
Is enGene Therapeutics' EPS (Diluted) too high?
enGene Therapeutics' current EPS (Diluted) is $-2.17. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' EPS (Diluted) compare to VTVT and GUTS?
enGene Therapeutics' EPS (Diluted) of $-2.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current EPS (Diluted) is $-2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current EPS (Diluted) of $-2.17. The current EPS (Diluted) is $-2.17. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current EPS (Diluted) is $-2.17 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score
Get the complete analysis for ENGN
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENGN has been successfully added to your 
